Eucodis: Antibody Drug Conjugate Using CTATTM Linker Technology Shows Superior Efficacy in Xenograft Trial.

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.

An anti-Her2 antibody conjugated to the maytansinoid DM1 using the novel CTATTM-linker technology (“CTAT-ADC”) was tested in nude mice with SKOV-3 cancer cell xenografts for maximum tolerated dose (“MTD”) and efficacy. Three different dosages of the CTAT-ADC were compared to a commercially available Trastuzumab-DM1-ADC (“T-DM1-ADC”, Kadcyla), to naked antibody and to the delivery vehicle. In the MTD part the CTAT-ADC was well tolerated by the animals in a dosage of up to 70 mg/kg body weight. No animals were lost, and only in the highest dosage group a slight and temporary loss of body weight was observed.

For the full press release please click here >>

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)